200 related articles for article (PubMed ID: 19920203)
1. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
[TBL] [Abstract][Full Text] [Related]
2. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
[TBL] [Abstract][Full Text] [Related]
4. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
6. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
van Waterschoot RA; Schinkel AH
Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
[TBL] [Abstract][Full Text] [Related]
7. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin.
Yan YD; Kim DH; Sung JH; Yong CS; Choi HG
Int J Pharm; 2010 Oct; 399(1-2):116-20. PubMed ID: 20727390
[TBL] [Abstract][Full Text] [Related]
9. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.
Koolen SL; van Waterschoot RA; van Tellingen O; Schinkel AH; Beijnen JH; Schellens JH; Huitema AD
J Clin Pharmacol; 2012 Mar; 52(3):370-80. PubMed ID: 21505085
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
Lee JH; Lee A; Oh JH; Lee YJ
Biopharm Drug Dispos; 2012 Nov; 33(8):474-86. PubMed ID: 22936118
[TBL] [Abstract][Full Text] [Related]
11. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
Dufek MB; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Tang SC; Kort A; Cheung KL; Rosing H; Fukami T; Durmus S; Wagenaar E; Hendrikx JJ; Nakajima M; van Vlijmen BJ; Beijnen JH; Schinkel AH
Mol Pharm; 2015 Oct; 12(10):3714-23. PubMed ID: 26317243
[TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Kuppens IE; Bosch TM; van Maanen MJ; Rosing H; Fitzpatrick A; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2005 Jan; 55(1):72-8. PubMed ID: 15316750
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
Dufek MB; Knight BM; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
Schuetz EG; Umbenhauer DR; Yasuda K; Brimer C; Nguyen L; Relling MV; Schuetz JD; Schinkel AH
Mol Pharmacol; 2000 Jan; 57(1):188-97. PubMed ID: 10617694
[TBL] [Abstract][Full Text] [Related]
16. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
Lee JH; Shin YJ; Kim HJ; Oh JH; Jang YP; Lee YJ
Int J Pharm; 2011 May; 410(1-2):68-74. PubMed ID: 21421030
[TBL] [Abstract][Full Text] [Related]
17. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
van Herwaarden AE; Wagenaar E; van der Kruijssen CM; van Waterschoot RA; Smit JW; Song JY; van der Valk MA; van Tellingen O; van der Hoorn JW; Rosing H; Beijnen JH; Schinkel AH
J Clin Invest; 2007 Nov; 117(11):3583-92. PubMed ID: 17975676
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
19. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
[TBL] [Abstract][Full Text] [Related]
20. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]